Back to results
US 2022/0177541 A1Published application
T cell receptors
AssigneeImmunocore Limited
InventorsPhilip William ADDIS, Nicole Joy BEDKE, Lucie BOUARD, Stephen HARPER, Nathaniel LIDDY, Tara MAHON, Ronan Pádraic O'DWYER
Life of this patent
Estimating the term…
Abstract
The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLQHLIGL (SEQ ID NO: 1) derived from the germline cancer antigen PRAME. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native PRAME TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
Claims11
A heterodimeric TCR-anti-CD3 antibody fusion molecule, wherein
- the alpha chain of the fusion molecule has the amino acid sequence set forth in SEQ ID NO:
- 25 and the beta chain of the fusion molecule has the amino acid sequence set forth in SEQ ID NO:
- 26;
- the alpha chain of the fusion molecule has the amino acid sequence set forth in SEQ ID NO:
- 27 and the beta chain of the fusion molecule has the amino acid sequence set forth in SEQ ID NO:
- 28;
- or
- the alpha chain of the fusion molecule has the amino acid sequence set forth in SEQ ID NO:
- 29 and the beta chain of the fusion molecule has the amino acid sequence set forth in SEQ ID NO:
- 30.
7 more elements
Dependencies are inferred from the claim text.